Dexbrompheniramine

For adults and adolescents aged 12 years and older, the standard dosing for dexbrompheniramine maleate depends on the formulation being used.

• Immediate-Release Formulations: The typical dose is 2 mg taken orally every 4 to 6 hours. Patients should not exceed 12 mg in a 24-hour period unless specifically directed by a physician.
• Timed-Release Formulations: The typical dose is 6 mg taken orally every 12 hours. The maximum daily dose for these formulations is generally 12 mg (two tablets) per 24 hours.

When used for the common cold, the medication should only be used for the duration of symptoms. For chronic allergic rhinitis, a healthcare provider may recommend a longer course of treatment, though second-generation antihistamines are often preferred for long-term management to avoid chronic sedation.

Pediatric dosing must be approached with extreme caution. The FDA and manufacturers have specific age-related guidelines to prevent toxicity.

• Children 12 years and older: Follow adult dosing (2 mg every 4-6 hours).
• Children 6 to under 12 years: The typical dose is 1 mg (usually half of an immediate-release tablet or a specific pediatric liquid dose) every 4 to 6 hours. Do not exceed 6 mg in 24 hours.
• Children under 6 years: Dexbrompheniramine is generally NOT recommended for children under the age of 6 due to the risk of over-sedation and paradoxical excitation (where the child becomes hyperactive instead of sleepy). Always consult a pediatrician before giving any antihistamine to a young child.

Renal Impairment

Because the kidneys are responsible for excreting the metabolites of dexbrompheniramine, patients with significant kidney disease (renal impairment) may require lower doses or longer intervals between doses. Accumulation of the drug can lead to increased toxicity and prolonged sedation.

Hepatic Impairment

Since the liver metabolizes dexbrompheniramine, individuals with liver cirrhosis or hepatitis should use this medication with caution. Dose reductions may be necessary to prevent the drug from reaching dangerous levels in the blood.

Elderly Patients

Patients over the age of 65 are more sensitive to the side effects of first-generation antihistamines. The American Geriatrics Society (Beers Criteria) generally recommends avoiding dexbrompheniramine in the elderly due to the high risk of confusion, dizziness, falls, and urinary retention. If use is absolutely necessary, the lowest possible dose should be initiated.

To ensure the safety and efficacy of dexbrompheniramine, patients should adhere to the following guidelines:

1. 1With or Without Food: Dexbrompheniramine can be taken with or without food. If the medication causes stomach upset, taking it with a meal or a glass of milk may help.
2. 2Swallow Whole: Timed-release or sustained-release tablets must be swallowed whole. Do not crush, chew, or break them, as this can cause the entire dose to be released at once, increasing the risk of side effects.
3. 3Measuring Liquids: If using an oral solution, always use a calibrated measuring device (like an oral syringe or dose cup). Do not use a household kitchen spoon, as these are not accurate for medical dosing.
4. 4Storage: Store the medication at room temperature (68°F to 77°F or 20°C to 25°C), away from moisture, heat, and direct light. Keep the container tightly closed and out of reach of children.

If you miss a dose, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and return to your regular schedule. Do not 'double up' or take extra medicine to make up for a missed dose, as this significantly increases the risk of overdose.

An overdose of dexbrompheniramine can be life-threatening, especially in children. Signs of overdose include extreme drowsiness, dilated pupils, flushed skin, fever, hallucinations, tremors, and seizures. In severe cases, it can lead to cardiovascular collapse or coma.

If an overdose is suspected, contact your local poison control center or seek emergency medical attention immediately. Treatment usually involves supportive care, such as gastric lavage (stomach pumping) if caught early, and monitoring of vital signs.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or stop taking this medication without medical guidance, especially if you are using it to manage chronic conditions.

As a first-generation antihistamine, dexbrompheniramine is frequently associated with side effects related to its ability to cross the blood-brain barrier and its interaction with muscarinic receptors.

• Somnolence (Drowsiness): This is the most common side effect. It can range from mild grogginess to deep sleep. This effect is often most pronounced during the first few days of treatment and may diminish as the body adjusts to the medication.
• Xerostomia (Dry Mouth): Due to its anticholinergic properties, dexbrompheniramine reduces saliva production. This can lead to a 'parched' feeling in the mouth and throat.
• Dizziness: Patients often report a sensation of lightheadedness or unsteadiness, particularly when moving from a sitting to a standing position.
• Thickening of Bronchial Secretions: The 'drying' effect can make mucus in the lungs thicker and harder to cough up, which may be problematic for individuals with underlying respiratory issues.

These side effects occur frequently enough to be noted by many patients but are not universal.

• Gastrointestinal Distress: This includes nausea, vomiting, epigastric distress (heartburn), or constipation.
• Blurred Vision: The medication can affect the eye's ability to focus by relaxing the ciliary muscle, leading to temporary blurring.
• Urinary Retention: Difficulty starting urination or an inability to fully empty the bladder, particularly in men with an enlarged prostate.
• Headache: Some patients experience mild to moderate tension-type headaches while taking the medication.
• Nervousness or Irritability: While most people feel sleepy, some individuals—especially children—may feel 'wired' or anxious.

Rarely, patients may experience more unusual reactions that require medical monitoring.

• Photosensitivity: Increased sensitivity of the skin to sunlight, leading to easier sunburns or rashes.
• Hematologic Changes: Rare cases of hemolytic anemia (destruction of red blood cells), agranulocytosis (low white blood cell count), or thrombocytopenia (low platelets) have been reported with antihistamines in this class.
• Hypotension: A drop in blood pressure, which may cause fainting (syncope).
• Tinnitus: A ringing or buzzing sound in the ears.

> Warning: Stop taking Dexbrompheniramine and call your doctor immediately if you experience any of these serious symptoms.

1. 1Severe Allergic Reaction (Anaphylaxis): Symptoms include hives, swelling of the face, lips, or tongue, and difficulty breathing or swallowing.
2. 2Seizures (Convulsions): Antihistamines can lower the seizure threshold in susceptible individuals.
3. 3Cardiac Arrhythmias: Rapid, pounding, or irregular heartbeats (palpitations) can occur, especially at higher doses.
4. 4Severe Confusion or Hallucinations: Particularly in elderly patients, the drug can cause significant mental status changes.
5. 5Severe Urinary Blockage: Complete inability to pass urine, which can lead to kidney pain or bladder damage.
6. 6Jaundice: Yellowing of the eyes or skin, which may indicate liver toxicity.

Dexbrompheniramine is generally intended for short-term use. Prolonged use (weeks or months) can lead to:

• Tolerance: The body may become less responsive to the drug's antihistamine effects over time, requiring higher doses for the same relief.
• Chronic Dryness: Long-term reduction in saliva can increase the risk of dental cavities and gum disease.
• Cognitive Decline: In older adults, chronic use of anticholinergic drugs has been linked in some observational studies to an increased risk of dementia and cognitive impairment.

Currently, there are no FDA black box warnings specifically for dexbrompheniramine maleate. However, it is important to note that the FDA has issued strong public health advisories against the use of OTC cough and cold medicines (which often contain dexbrompheniramine) in children under the age of 4, and many manufacturers have voluntarily updated their labels to exclude children under 6.

Report any unusual symptoms or persistent side effects to your healthcare provider. Monitoring is essential to ensure the benefits of the medication outweigh the risks of these side effects.

Dexbrompheniramine is a potent medication that affects the central nervous system (CNS) and the autonomic nervous system. Patients must be aware that the primary safety concern is its sedative effect. This medication can significantly impair mental alertness and physical coordination. Because it remains in the system for a long time (up to 30 hours), these effects may persist well into the day after a dose is taken.

There are no FDA-mandated black box warnings for dexbrompheniramine at this time. It is considered safe and effective when used exactly as directed by a healthcare professional or according to the 'Drug Facts' label on over-the-counter products.

CNS Depression and Alcohol

Dexbrompheniramine is a CNS depressant. Using it alongside other substances that slow down brain activity—such as alcohol, benzodiazepines (anti-anxiety meds), or opioid pain medications—can lead to dangerous levels of respiratory depression, extreme lethargy, and even coma.

Respiratory Conditions

Patients with chronic obstructive pulmonary disease (COPD), asthma, or emphysema should use dexbrompheniramine with extreme caution. The anticholinergic 'drying' effect can thicken mucus in the airways, making it much harder to clear the lungs during an infection or asthma attack, potentially worsening the condition.

Glaucoma and Eye Pressure

This medication can increase intraocular pressure (pressure inside the eye). It is generally contraindicated or requires very close monitoring in patients with narrow-angle glaucoma, as it could trigger an acute glaucoma attack, which is a medical emergency.

Prostatic Hypertrophy and Urinary Obstruction

Men with an enlarged prostate (benign prostatic hyperplasia) may find that dexbrompheniramine makes it significantly harder to urinate. In some cases, it can cause acute urinary retention, requiring catheterization.

Cardiovascular Disease

While less common, antihistamines can cause tachycardia (fast heart rate) and palpitations. Patients with a history of heart disease, hypertension (high blood pressure), or ischemic heart disease should consult their cardiologist before use.

For short-term use, extensive lab monitoring is usually not required. However, if a patient is prescribed dexbrompheniramine for longer periods, healthcare providers may monitor:

• Liver Function Tests (LFTs): To ensure the liver is processing the drug correctly.
• Kidney Function (BUN/Creatinine): To ensure the drug is being cleared from the body.
• Blood Pressure: To check for any cardiovascular impact.

Do not drive, operate heavy machinery, or engage in hazardous activities until you know how dexbrompheniramine affects you. The impairment caused by first-generation antihistamines has been compared in clinical studies to the impairment caused by alcohol consumption. Even if you do not 'feel' sleepy, your reaction times may be significantly slowed.

Alcohol must be avoided while taking dexbrompheniramine. Alcohol significantly enhances the sedative effects of the drug, increasing the risk of accidents, falls, and severe respiratory depression.

For most people taking dexbrompheniramine for allergies or a cold, the medication can be stopped abruptly without a tapering schedule. However, if you have been taking it daily for an extended period, you may experience 'rebound' symptoms, such as increased nasal congestion or difficulty sleeping, for a few days after stopping.

> Important: Discuss all your medical conditions, especially respiratory or eye problems, with your healthcare provider before starting Dexbrompheniramine.

Certain medications should never be combined with dexbrompheniramine due to the risk of severe, life-threatening reactions.

• Monoamine Oxidase Inhibitors (MAOIs): Drugs such as phenelzine, selegiline, or tranylcypromine must not be taken with dexbrompheniramine. MAOIs prolong and intensify the anticholinergic effects of antihistamines. This combination can lead to severe hypotension (low blood pressure), seizures, and high fevers. You should wait at least 14 days after stopping an MAOI before starting dexbrompheniramine.

• CNS Depressants: This includes barbiturates, benzodiazepines (e.g., alprazolam, lorazepam), and sleep medications (e.g., zolpidem). Combining these with dexbrompheniramine causes additive CNS depression, which can lead to profound sedation and respiratory failure.
• Opioid Analgesics: Medications like codeine, hydrocodone, or oxycodone also cause sedation. When taken with dexbrompheniramine, the risk of extreme drowsiness and constipation increases significantly.
• Potassium Chloride (Oral): Anticholinergics like dexbrompheniramine slow down the movement of the gut. This can cause solid potassium tablets to sit in the esophagus or stomach for too long, leading to severe irritation or ulcers.

• Tricyclic Antidepressants (TCAs): Drugs like amitriptyline or nortriptyline have their own anticholinergic properties. Using them with dexbrompheniramine can lead to 'anticholinergic overload,' characterized by severe dry mouth, constipation, and blurred vision.
• Other Antihistamines: Taking multiple antihistamines (including topical creams) increases the risk of side effects without necessarily increasing the benefit.

• Alcohol: As noted, alcohol is the most significant interaction. It acts synergistically with dexbrompheniramine to depress the central nervous system.
• Grapefruit Juice: While not as severely affected as some other drugs, certain components in grapefruit can interfere with the enzymes that break down antihistamines, potentially leading to higher levels of the drug in the blood.

• St. John’s Wort: May induce the enzymes that metabolize dexbrompheniramine, potentially making the medication less effective.
• Valerian Root, Kava, and Melatonin: These supplements are often used for sleep or anxiety. Because they also cause sedation, they should be used with caution as they will increase the drowsiness caused by dexbrompheniramine.

• Allergy Skin Tests: Dexbrompheniramine can prevent or diminish the skin's reaction to allergens during a scratch test. You must typically stop taking all antihistamines at least 3 to 7 days before undergoing allergy skin testing to ensure accurate results.

For each major interaction, the mechanism usually involves either pharmacodynamic synergy (both drugs doing the same thing to the body, like causing sleepiness) or pharmacokinetic interference (one drug changing how the other is absorbed or broken down).

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete medication review is the best way to prevent dangerous drug interactions.

There are several conditions where the risks of dexbrompheniramine far outweigh any potential benefits. In these cases, the medication must never be used.

1. 1Hypersensitivity: Anyone with a known allergy to dexbrompheniramine, brompheniramine, or any other antihistamines in the alkylamine class (such as chlorpheniramine) should avoid this drug. An allergic reaction could lead to anaphylaxis.
2. 2MAOI Therapy: As mentioned in the interactions section, use within 14 days of an MAO inhibitor is strictly prohibited due to the risk of severe anticholinergic crisis.
3. 3Narrow-Angle Glaucoma: Because dexbrompheniramine can increase pressure within the eye, it can cause permanent vision loss in those with this specific type of glaucoma.
4. 4Stenosing Peptic Ulcer or Pyloroduodenal Obstruction: The anticholinergic effects slow down gastric emptying and can worsen a blockage in the digestive tract.
5. 5Symptomatic Prostatic Hypertrophy: If a patient is already having significant trouble urinating due to an enlarged prostate, this medication can cause a complete and painful blockage of the bladder neck.
6. 6Newborns and Premature Infants: The risk of severe respiratory depression and sudden death is too high in this population.

These are conditions where the medication should only be used if a doctor determines the benefit is essential and can monitor the patient closely.

• Asthma: While not an absolute contraindication, the drying of secretions can be dangerous during an acute exacerbation.
• Cardiovascular Disease: Including hypertension and ischemic heart disease, due to the risk of tachycardia.
• Hyperthyroidism: Antihistamines can sometimes worsen the symptoms of an overactive thyroid, such as a fast heart rate.

Patients who have had a bad reaction to Chlorpheniramine (Chlor-Trimeton) or Brompheniramine (Dimetapp) are very likely to have a similar reaction to dexbrompheniramine. These drugs are chemically related, and the body's immune system often recognizes them in the same way. Always inform your pharmacist if you have reacted poorly to any 'cold and allergy' medicine in the past.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Dexbrompheniramine. Do not assume an over-the-counter medication is safe for you without checking first.

Dexbrompheniramine is generally classified as FDA Pregnancy Category B. This means that animal reproduction studies have failed to demonstrate a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women.

• First Trimester: Most doctors recommend avoiding all unnecessary medications during the first trimester when organ development is most critical.
• Third Trimester: Use near the end of pregnancy should be avoided, as newborns (especially premature ones) are highly sensitive to the effects of antihistamines, which can cause severe reactions or seizures.

Always consult an obstetrician before using dexbrompheniramine during pregnancy.

Dexbrompheniramine is known to pass into breast milk in small amounts. Because infants are more susceptible to the side effects of antihistamines (such as unusual irritability or drowsiness), use while breastfeeding is generally discouraged. Furthermore, because of its anticholinergic effects, dexbrompheniramine can actually suppress lactation, making it harder for the mother to produce enough milk for the baby.

As noted, dexbrompheniramine is not approved for use in children under 6 years of age by most guidelines. In children who do take it, 'paradoxical excitation' is a common concern. Instead of becoming sleepy, the child may become extremely hyperactive, experience tremors, or have trouble sleeping. Overdose in children is a medical emergency and can lead to hallucinations and death.

According to the Beers Criteria for Potentially Inappropriate Medication Use in Older Adults, dexbrompheniramine is listed as a drug to be avoided. Older adults have a higher 'anticholinergic burden,' meaning their bodies are more sensitive to drugs that block acetylcholine. In this population, dexbrompheniramine significantly increases the risk of:

• Falls and Fractures: Due to dizziness and sedation.
• Delirium: Acute confusion and disorientation.
• Urinary Retention: Leading to bladder infections.
• Constipation: Which can become severe.

In patients with a Glomerular Filtration Rate (GFR) below 50 mL/min, the interval between doses should be increased. If the kidneys cannot filter the drug's metabolites, they will build up in the blood, leading to 'antihistamine toxicity,' characterized by extreme lethargy and dry membranes.

Patients with Child-Pugh Class B or C liver disease should be started on the lowest possible dose (e.g., 1 mg instead of 2 mg) and monitored for signs of over-sedation. The liver's ability to clear the drug is the primary factor in determining how long the drug stays active in the body.

> Important: Special populations require individualized medical assessment. Never share your medication with others, especially children or the elderly.

Dexbrompheniramine maleate is a potent H1-receptor antagonist. At the molecular level, it acts as a competitive inhibitor. It binds to the H1 receptors on the surface of effector cells but does not activate them. By 'parking' in the receptor, it prevents histamine from binding. This prevents the activation of phospholipase C and the subsequent increase in intracellular calcium that normally leads to smooth muscle contraction and increased vascular permeability (swelling).

Additionally, dexbrompheniramine has a high affinity for muscarinic acetylcholine receptors. By blocking these receptors, it inhibits the parasympathetic nervous system's 'rest and digest' signals to the glands in the nose and mouth, leading to the clinical 'drying' effect.

The onset of action for dexbrompheniramine is typically 15 to 30 minutes after oral ingestion. The peak antihistamine effect occurs between 3 and 6 hours. While the allergy-blocking effects may last for 8 to 12 hours, the sedative effects can last significantly longer due to the drug's long half-life. Tolerance to the sedative effects may develop after several days of continuous use, but the H1-blocking efficacy generally remains stable.

| Parameter | Value |

|---|---|

| Bioavailability | Approximately 70-80% |

| Protein Binding | 69% to 72% |

| Half-life | 20 to 30 hours |

| Tmax | 2 to 3 hours |

| Metabolism | Hepatic (CYP450 system) |

| Excretion | Renal (primarily as metabolites) |

• Molecular Formula: C16H19BrN2 • C4H4O4
• Molecular Weight: 435.3 g/mol (as maleate salt)
• Solubility: Soluble in water and alcohol.
• Structure: It is a propylamine derivative. The 'dex' prefix refers to the dextrorotatory enantiomer, which provides the majority of the pharmacological activity of the racemic mixture.

Dexbrompheniramine is classified as a First-Generation Antihistamine and specifically belongs to the Alkylamine subclass. Other drugs in this subclass include chlorpheniramine and triprolidine. Alkylamines are generally known for causing less sedation than ethanolamines (like diphenhydramine/Benadryl) but still significantly more than second-generation drugs.